| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More | Frank Vinluan | 07/19/19 | National |
| Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control | Ben Fidler | 01/04/18 | Boston |
| Gilman’s Next CEO Trick: Taming CAR-T Cells With Obsidian | Ben Fidler | 12/06/17 | Boston |
| Bio Roundup: Barron Joins GSK, Sage Bounces Back, Valeant Dumps Addyi | Ben Fidler | 11/10/17 | National |
| Bio Roundup: Trumpcare Is Mean, SCOTUS Says Go, Merck’s Myeloma No | Ben Fidler | 06/16/17 | National |
| Investors Sour on Data Debut For Dimension’s Hemophilia Gene Therapy | Ben Fidler | 01/31/17 | Boston |
| Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More | Alex Lash | 12/09/16 | National |
| Fresh Off ASH Data, Spark Teams With Selecta to Boost Gene Therapies | Ben Fidler | 12/05/16 | Boston |
| Novan Files for IPO to Finance ‘Nitric Oxide on Demand’ Skin Drugs | Frank Vinluan | 08/25/16 | Raleigh Durham |
| Gemphire’s Delayed $30M IPO Will Pay for Trials of Cholesterol Drug | Sarah Schmid Stevenson | 08/10/16 | Detroit Ann Arbor |
| Harvard’s Springer Gets $51.5M From Pharmas, Others, For Latest Startup | Ben Fidler | 06/30/16 | Boston |
| Syros Cuts Price But Bags $50M in IPO to Fuel Cancer Drug Trials | Ben Fidler | 06/29/16 | Boston |
| Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More | Ben Fidler | 06/24/16 | National |
| Many Biotechs Need Inside IPO Help, But Selecta Is An Extreme Case | Ben Fidler | 06/22/16 | Boston |
| Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More | Ben Fidler | 06/10/16 | National |
| Biotech Roundup: Duchenne Delay, Forum’s Fate, Califf, Ionis & More | Ben Fidler | 05/27/16 | National |
| Retooled Selecta Bio Takes Crossover Cash to IPO Queue | Ben Fidler | 05/24/16 | Boston |
| East Coast Biotech Roundup: Biogen, Watson, Data Dumps & More | Ben Fidler | 09/11/15 | Boston |
| Selecta, Eyeing IPO, Brings Sanofi, Crossovers Aboard For $38M Round | Ben Fidler | 09/08/15 | Boston |
| Selecta Biosciences Receives $38,000,000 Series E Round | VentureDeal | 09/08/15 | Boston |
| East Coast Biotech Roundup: Vertex, Moderna, Sage, ASCO & More | Ben Fidler | 05/15/15 | Boston |
| Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals | Ben Fidler | 05/13/15 | Boston |
| MassChallenge Winner From MIT Aims to Kill Cancer With a “Squeeze” | Ben Fidler | 11/24/14 | Boston |
| East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More | Ben Fidler | 10/16/14 | Boston |
| Selecta, Sharpening Focus, Gets $20M More to Make Biologics Safer | Ben Fidler | 10/15/14 | Boston |
| Selecta Biosciences Secures $20,000,000 New Funding Round | VentureDeal | 10/15/14 | Boston |
| Selecta Biosciences Receives $4,450,000 New Funding Round | VentureDeal | 08/29/14 | Boston |
| East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More | Ben Fidler | 06/20/14 | Boston |
| Selecta Biosciences Garners $9,350,000 New Financing | VentureDeal | 06/18/14 | Boston |
